These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3228592)

  • 41. Estrogen receptors and breast cancer: prognostic and therapeutic implications.
    Gapinski PV; Donegan WL
    Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences.
    Ruder AM; Lubin F; Wax Y; Geier A; Alfundary E; Chetrit A
    Cancer; 1989 Jul; 64(1):196-202. PubMed ID: 2731116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease.
    Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Branković-Magić M; Kanjer K; Gavrilović D; Mitrović L; Borojević N; Vukotić D; Spuzić I
    J Exp Clin Cancer Res; 1999 Sep; 18(3):347-55. PubMed ID: 10606181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study.
    Vettuparambil A; Chirukandath R; Culas TB; Vijayan SM; Rajan G; Kuttappan SV
    World J Surg Oncol; 2015 Apr; 13():160. PubMed ID: 25899789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of ovariectomy on excretion of urinary steroids and tumor growth in rats bearing 7,12-dimethylbenz[a]anthracene-induced mammary cancer.
    Nakamura Y; Kodama M; Kodama T
    Gan; 1982 Apr; 73(2):234-8. PubMed ID: 6811362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies.
    Falkson G; Gelman RS; Leone L; Falkson CI
    Cancer; 1990 Oct; 66(7):1621-9. PubMed ID: 2208013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long-term prognostic role of steroid receptors in cancer of the breast].
    Broët P; Pichon MF; Magdelenat H; Delarue JC; Spyratos F; Basuyau JP; Saez S; Rallet A; Courrière P; Millon R; Asselain B
    Bull Cancer; 1998 Apr; 85(4):347-52. PubMed ID: 9752299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients.
    Blanco G; Alavaikko M; Ojala A; Collan Y; Heikkinen M; Hietanen T; Aine R; Taskinen PJ
    Anticancer Res; 1984; 4(6):383-9. PubMed ID: 6097159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
    J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brunelli A; Brizzi MP; Di Marco B; Cirillo F; Tampellini M; Bolsi G; Aguggini S; Betri E; Filippini L; Bertoli A; Alquati P; Dogliotti L
    Int J Oncol; 1998 Aug; 13(2):385-90. PubMed ID: 9664137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor.
    Damstrup L; Andersen J; Kufe DW; Hayes DF; Poulsen HS
    Ann Oncol; 1992 Jan; 3(1):71-7. PubMed ID: 1606073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor.
    Cooper LS; Gillett CE; Patel NK; Barnes DM; Fentiman IS
    Cancer; 1999 Nov; 86(10):2053-8. PubMed ID: 10570431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
    Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term response to ovariectomy in 35 premenopausal patients with advanced breast cancer, treated in coherence with hormonal tests.
    Preda F; Oriana S; Di Fronzo G; Secreto G; Severini A; Scavone G; Castagnola G
    Tumori; 1983 Aug; 69(4):343-7. PubMed ID: 6623658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
    Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
    J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
    Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
    J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.